Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
Angew Chem Int Ed Engl. 2018 Sep 3;57(36):11608-11612. doi: 10.1002/anie.201804875. Epub 2018 Aug 6.
For optical control of GPCR function, we set out to develop small-molecule ligands with photoswitchable efficacy in which both configurations bind the target protein but exert distinct pharmacological effects, that is, stimulate or antagonize GPCR activation. Our design was based on a previously identified efficacy hotspot for the peptidergic chemokine receptor CXCR3 and resulted in the synthesis and characterization of five new azobenzene-containing CXCR3 ligands. G protein activation assays and real-time electrophysiology experiments demonstrated photoswitching from antagonism to partial agonism and even to full agonism (compound VUF16216). SAR evaluation suggests that the size and electron-donating properties of the substituents on the inner aromatic ring are important for the efficacy photoswitching. These compounds are the first GPCR azo ligands with a nearly full efficacy photoswitch and may become valuable pharmacological tools for the optical control of peptidergic GPCR signaling.
为了实现 GPCR 功能的光学控制,我们着手开发具有光致切换效力的小分子配体,其中两种构象都能与靶蛋白结合,但产生不同的药理效应,即刺激或拮抗 GPCR 的激活。我们的设计基于先前鉴定的肽类趋化因子受体 CXCR3 的一个有效作用热点,由此合成并表征了五种新型含偶氮苯的 CXCR3 配体。G 蛋白激活测定和实时电生理学实验表明,配体可从拮抗作用切换为部分激动作用,甚至完全激动作用(化合物 VUF16216)。SAR 评估表明,内环上取代基的大小和供电子性质对效力光致切换很重要。这些化合物是第一批具有近乎全效光致切换的 GPCR 偶氮配体,可能成为光控肽类 GPCR 信号的有价值的药理学工具。